Skip to main content

Free Content Tolerability of amodiaquine and sulphadoxine-pyrimethamine, alone or in combination for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan adults

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

Summary Objective 

To assess the tolerability and efficacy of amodiaquine (AQ) + sulphadoxine-pyrimethamine (SP), the first-line malaria treatment in Rwanda. Method 

Randomized, double-blind trial in 2003 in Kigali town. A total of 351 adult patients with uncomplicated Plasmodium falciparum malaria were randomly allocated to one of the following treatments: AQ + SP, AQ or SP. We followed patients until day 14 after treatment and recorded adverse events (AEs) and clinical and parasitological outcomes. Results 

One hundred and eighteen patients reported at least one AE: 40% in the AQ, 39% in the AQ + SP and 21% in the SP groups. The AE was classified as possibly related to the antimalarial treatment for 86 patients. The Risk Ratio for at least one AE after treatment was significantly and about fourfold higher in patients receiving AQ or AQ + SP than in patients receiving SP. Pruritus and fatigue were significantly more frequent in patients treated with AQ or AQ + SP than in those receiving SP. Severe AEs, such as fatigue, nausea, dizziness and vomiting, were observed in four patients treated with AQ, in 10 treated with AQ + SP and in one patient treated with SP. Conclusion 

Amodiaquine + SP is not well tolerated and a substantial proportion of patients experienced pruritus and fatigue, thus decreasing their compliance and compromising the first line treatment implementation at national level. This renders AQ-containing regimens sub-optimal; better-tolerated treatments should be identified.

Keywords: Plasmodium falciparum malaria; Rwanda; amodiaquine; sulphadoxine-pyrimethamine; tolerability

Document Type: Research Article

DOI: https://doi.org/10.1111/j.1365-3156.2006.01610.x

Affiliations: 1:  National Malaria Control Program, Kigali, Rwanda 2:  Belgian Technical Cooperation, Kigali, Rwanda 3:  Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium

Publication date: 2006-05-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more